Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies

OBJECTIVE: To evaluate onset of effect of galcanezumab in patients with episodic migraine. BACKGROUND: Galcanezumab is a monoclonal antibody that binds to calcitonin gene‐related peptide and is indicated for preventive treatment of migraine. DESIGN/METHODS: Data on the primary outcome measure were a...

Descripción completa

Detalles Bibliográficos
Autores principales: Detke, Holland C., Millen, Brian A., Zhang, Qi, Samaan, Karen, Ailani, Jessica, Dodick, David W., Aurora, Sheena K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028148/
https://www.ncbi.nlm.nih.gov/pubmed/31710104
http://dx.doi.org/10.1111/head.13691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028148/
https://www.ncbi.nlm.nih.gov/pubmed/31710104
http://dx.doi.org/10.1111/head.13691

Ejemplares similares